ÂÜÀòÂÒÂ×

Dr. Robin L Smith, MD, MBA is a business leader, entrepreneur, medical doctor and philanthropist. She is a pioneer in the fields of regenerative medicine and predictive analytics. Previously as a Chairman and CEO of Neostem (NASDAQ: NBS), she transformed the company’s proprietary cell therapy development into an innovative business model leading to its acquisition by Hitachi at 8x the price it had been acquired.

An accomplished author on the topic of cell therapeutics, Dr. Smith was appointed as clinical associate professor, Department of Medicine at the Rutgers, New Jersey Medical School in 2017. She has received many accolades for her tireless efforts in healthcare industry, which include; the Regenerative Medicine Foundation (RMF) 2019 Stem Cell and Regenerative Medicine Action Award for International Diplomacy, the 2018 HEALinc Future Health Humanitarian Award, the Business Intelligence Group’s Woman of the Year Award in 2018 and the 2018 Gold Stevie® Award for Woman of the Year – Government or Non-Profit. In April 2016, Pope Francis awarded Dr. Smith Dame Commander with Star Pontifical Equestrian Order of Saint Sylvester Pope and Martyr. In May 2017, she was also awarded the Lifetime Achievement in Healthcare and Science Award by The National Museum of Catholic Art and Library.

Dr. Smith received her B.A. degree from Yale University and her M.D. degree from the Yale School of Medicine. She holds an M.B.A. degree from the Wharton School of Business and completed the Stanford University Directors Program. In 2019, she received an honorary Doctor of Science degree from Thomas Jefferson Medical College.

Dr. Smith currently serves on the boards of Sorrento Therapeutics (NASDAQ: SRNE), ServiceSource International, Inc. as well as Celularity Inc, a Celgene spin-out focused on cancer and regenerative medicine. She is also active in many nonprofit organizations such as the Cura Foundation and Stem for Life. She serves as a member of the board of trustees of the Sanford Health International Board, the Alliance for Regenerative Medicine (ARM) Foundation, Unite to Prevent Cancer (UTPC) Foundation and the Alliance for Cell Therapy Now. She also serves on the board of overseers of the New York University Langone Medical Center in New York and previously served on the board of trustees of the New York University Langone Medical Center and was chairman of the board of directors of the New York University Hospital for Joint Diseases.